Correlation Engine 2.0
Clear Search sequence regions

  • clonazepam (3)
  • cystitis (1)
  • diagnosis (1)
  • dry mouth (1)
  • female (1)
  • fibromyalgia (3)
  • humans (1)
  • low (5)
  • mouth (6)
  • pain chronic (1)
  • patient (2)
  • protocol (1)
  • tongue (1)
  • woman (1)
  • Sizes of these terms reflect their relevance to your search.

    The International Classification of Disease defines burning mouth syndrome (BMS) as a chronic intraoral burning sensation, with no identifiable local or systemic cause. Since current management is often unsatisfactory, the aim of this report is to describe a new treatment modality (i.e., low-dose naltrexone [LDN]). A 62-year-old woman presented with the complaint of burning on the tongue of 3 years' duration. Existing comorbidities were fibromyalgia, irritable bowel syndrome, headache, and interstitial cystitis. Her reported pain intensity ranged from 2/10 (morning) to 8/10 (evening) on a numeric rating scale. With the diagnosis of BMS and hyposalivation, and in light of her current clonazepam use and fibromyalgia, a dry mouth protocol and LDN (3 mg) were prescribed. After 1 month, her pain intensity decreased by 50%, with no pain upon awakening. After 2 months, the widespread pain associated with her chronic morbidities also reduced by 50%, and her headache disappeared. After adjusting LDN dose to 4.5 mg, the patient was stable at 6 months, with 50% reduction of widespread pain and 2/10 BMS pain, and no reported side effects. These preliminary results suggest that LDN may be a feasible and effective treatment for BMS, especially in patients' refractory to traditional treatment. Copyright © 2022 Elsevier Inc. All rights reserved.


    Linda Sangalli, Craig S Miller. Low-dose naltrexone for treatment of burning mouth syndrome. Oral surgery, oral medicine, oral pathology and oral radiology. 2023 Apr;135(4):e83-e88

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35851249

    View Full Text